A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

被引：9
|
作者：
Inoue, A. [1 ]
Kobayashi, K. [2 ]
Maemondo, M. [3 ]
Sugawara, S. [4 ]
Oizumi, S. [5 ]
Saijo, Y. [6 ]
Genma, A. [7 ]
Morita, S. [8 ]
Hagiwara, K. [2 ]
Nukiwa, T. [9 ]
机构：
[1] Tohoku Univ Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[2] Saitama Med Univ, Dept Resp Med, Saitama, Japan
[3] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi 9811293, Japan
[4] Sendai Kosei Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[5] Hokkaido Univ, Grad Sch Med, Dept Internal Med 1, Sapporo, Hokkaido, Japan
[6] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan
[7] Nippon Med Sch, Dept Resp Med, Tokyo 113, Japan
[8] Yokohama City Univ, Dept Stat, Yokohama, Kanagawa 232, Japan
[9] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Miyagi 980, Japan
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(09)72038-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Saijo, Y.
    Yoshizawa, H.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002
    Osamu, Ishimoto
    Kobayashi, Kunihiko
    Inoue, Akira
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Saijo, Yasuo
    Gemma, Akihiko
    Morita, Satoshi
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
  • [3] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group
    Kobayashi, K.
    Inoue, A.
    Maemondo, M.
    Sugawara, S.
    Isobe, H.
    Oizumi, S.
    Saijo, Y.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
    Miyauchi, Eisaku
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 670 - 676
  • [5] LONG-TERM SURVIVORS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM A RANDOMIZED PHASE III STUDY COMPARING GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)
    Minegishi, Y.
    Kobayashi, K.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Oizumi, S.
    Hagiwara, K.
    Nukiwa, T.
    Morita, S.
    Gemma, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 412 - 412
  • [6] PROGNOSTIC FACTORS IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM THE RANDOMIZED PHASE III STUDY COMPARED GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)
    Minegishi, Y.
    Kobayashi, K.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Ohizumi, S.
    Isobe, H.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    Gemma, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
  • [7] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [8] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Harada, M.
    Yoshizawa, H.
    Kinoshita, I.
    Fujita, Y.
    Okinaga, S.
    Hirano, H.
    Yoshimori, K.
    Harada, T.
    Saijo, Y.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 54 - 59
  • [9] First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group
    Minegishi, Y.
    Inoue, A.
    Kobayashi, K.
    Gemma, A.
    Maemondo, M.
    Oizumi, S.
    Saijo, Y.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (04): : 25 - 25
  • [10] A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Paz-Ares, L.
    Balint, B.
    de Boer, R.
    van Meerbeeck, J. P.
    Wierzbicki, R.
    Desouza, P. L.
    Galimi, F.
    Haddad, V.
    Hei, Y.
    Ramlau, R.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 137 - 137
12345